Home Alzheimer’s Disease Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease–Associated RCC

Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease–Associated RCC

At the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, researchers showed that MK-6482 induced clinical responses among patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma (RCC).

Eric Jonasch, MD, professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center, spoke to CancerNetwork about next steps for those with von Hippel-Lindau disease–associated renal cell carcinoma being treated with the HIF-2a Inhibitor, MK-6482.



The hope here is that this agent be approved and that in individuals who do have lesions that are starting to get to a size where they might need some type of intervention that they could get this drug instead of a surgical intervention and that they could be on this for some period of time. That would either delay or prevent the need for that surgical…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments